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An Evaluation of Health Diagnostic Laboratory, Inc.
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Dawn Thiselton, PhD,2 Shahrzad Grami, MS,2 Ralph M. Turner, PhD,3 and John Barron, PharmD3
Abstract
In an effort to reduce cost and improve quality, health care payers have enacted a number of incentives to
motivate providers to focus their efforts on achieving better clinical outcomes and reducing the prevalence and
progression of disease. In response to these incentives, providers are entering into new arrangements such as
accountable care organizations and patient-centered medical homes to redesign delivery processes and achieve
quality and cost objectives. This article reports the results of a study designed to evaluate the impact on cost and
quality of care resulting from services provided by Health Diagnostic Laboratory, Inc., a clinical laboratory with
a comprehensive care model. The results show that patients who utilized these laboratory services experienced
lower total cost of care (23% reduction, P< 0.01) and improved lipid profiles during the follow-up period. Total
cost reductions were related to cost reductions found in both inpatient and ambulatory care. These findings
suggest that accountable care organizations, patient-centered medical homes, and other groups entering shared
savings initiatives should consider the potential role ancillary service providers with comprehensive care models
can play in the delivery of integrated care. (Population Health Management 2014;17:121–126)
Introduction
Over the past several years, public and private payershave implemented a number of payment reform efforts
designed to hold providers more accountable for the quality of
care they deliver and to put greater focus on limiting the
prevalence and progression of disease. At the federal and state
level, reform efforts have been centered on Medicare and
Medicaid programs. In some cases, the programs were de-
signed to provide incentives for providers to adopt practices
and technologies indirectly associated with more efficient,
higher quality care. For example, the American Recovery and
ReinvestmentAct of 2009 included the enactment of theHealth
Information Technology for Economic and Clinical Health Act,
which contained grant provisions, followed by penalties, to
encourage the adoption of electronic medical record systems.
Other programs, such as the Medicare Shared Savings
Program, directly tie improved outcomes to reimbursement.
Under the Medicare Shared Savings Program, providers are
paid standard Medicare rates and receive bonus payments if
total cost of care is below a predetermined benchmark and if
quality thresholds are met. As of August 2012, a total of 116
organizations covering more than 4 million individuals had
entered into shared savings agreements with the Centers for
Medicare and Medicaid Services.1,2
Private payers are following suit and various initiatives
are under way to explore the effectiveness of payment
models that combine fee for service, capitation, payment for
quality thresholds, and shared savings. More than 8 private
insurers, including Aetna, Anthem, and Blue Cross Blue
Shield plans in Illinois, Massachusetts, New Jersey, and
North Carolina, are exploring such options.3 In some cases,
providers can receive a portion of shared savings but face no
penalty if savings are not realized. In other cases, providers
pay penalties if actual health care costs are above the total
cost of care target. In order to achieve savings goals, pro-
viders are transforming the provision of health care services
in order to improve the coordination of care, improve the
timing and accuracy of decisions, and reconfigure clinical
processes to reduce errors. The most common examples of
these new delivery models are the patient-centered medical
home (PCMH) and the accountable care organization (ACO).
1Robins School of Business, University of Richmond, Richmond, Virginia.
2Health Diagnostic Laboratory, Inc., Richmond, Virginia.
3HealthCore, Inc., Wilmington, Delaware.
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Patient-centered medical homes
A PCMH is a certified primary care practice that provides
ongoing evidence that it is capable of providing care reflec-
tive of the principles of primary care: (1) an ongoing rela-
tionship with a personal physician for comprehensive care;
(2) a physician- or nurse practitioner-directed team that is
capable of meeting all the patient’s needs; (3) a holistic focus;
(4) coordinated care across the entire health care system and
the patient’s community; (5) safe, quality care through evi-
dence-based medicine, effective use of information technol-
ogy, and continuous improvement; and (6) enhanced access
through expanded hours and alternate forms of communi-
cation.4 PCMH initiatives also include payment reform
whereby providers receive bonus payments for achieving
quality of care thresholds. Thus far, results of PCMH initia-
tives are mixed. Some studies have found that PCMHs are
associated with better outcomes and lower total cost.5,6 In
contrast, other studies have shown that, although PCMHs
are effective at improving the patient experience and im-
proving quality of care, there is no statistically significant
reduction in total cost of care when compared to control
groups receiving care at traditional physician practices.7
Accountable care organizations
In contrast to the primary care focus of the PCMH, an
ACO is formed when there is an arrangement between a
payer and provider(s) to offer a complete spectrum of patient
care services for a defined population. The ACO may com-
prise a single organization that is vertically integrated to
provide primary, secondary, and tertiary care (eg, Mayo
Clinic), or, more commonly, it may comprise a group of
providers that collectively offer a complete range of health
services. Similar to the PCMH, in order to receive bonus
payments the ACO must reduce the total cost of care below a
predetermined threshold while simultaneously meeting
quality benchmarks. Although ACO initiatives are relatively
new, early evidence suggests that most health care organi-
zations struggle to manage populations of patients effec-
tively, and the results of recent ACO initiatives in terms of
cost savings are mixed.8
Changing role of ancillary services
In response to the mixed results achieved by PCMHs and
ACOs thus far, new initiatives seek to determine how to
configure the composition, roles, and responsibilities of the
provider teams that comprise the PCMH and the ACO. In-
itial PCMH and ACO efforts were focused predominately on
improving the communication between health care institu-
tions (eg, hospitals, rehabilitation centers) and on the be-
haviors of direct health care providers (eg, physicians). More
recent initiatives are expressly changing how ancillary health
care providers enter the health care delivery process. One
example is the Vermont Blueprint for Health. Vermont has
spearheaded an effort to proliferate PCMHs that incorporate
so-called community health teams (CHT).9 The role of the
CHT is to provide multidisciplinary support for PCMHs and
their patients and to integrate PCMHs with community re-
sources. Health Diagnostic Laboratory, Inc. (HDL, Inc.), a
clinical laboratory headquartered in Richmond, Virginia, and
the subject of this study, is another example of the changing
role of ancillary services. In addition to specimen processing
and reporting, HDL, Inc. offers a comprehensive care model
that links providers, patients, and clinical health consultants
(CHCs) to help ensure that the appropriate tests are followed
by evidence-based interventions, with subsequent lifestyle
changes and counseling to promote wellness.
The HDL, Inc. model
HDL, Inc. offers comprehensive laboratory testing that in-
cludes serum biomarkers and genetic screening, enabling
physicians to identify ‘‘at-risk’’ patients prior to a disease
progressing to the point where an adverse event occurs or
complex/invasive procedures are needed. In addition to
performing clinical laboratory services, HDL, Inc. offers free
supplemental services to providers and patients. Along with
the laboratory results, providers receive guidelines for pre-
scribing medication plus diet and exercise recommendations.
These guidelines allow providers to develop personalized
treatment plans quickly, targeted to patients’ risk profiles (eg,
heart disease, diabetes, metabolic syndrome). Patients receive
a Web-based personal health record and patient portal that
enables them to share information electronically with pro-
viders of their choosing, and free access to trained CHCs.
CHCs are pivotal to the HDL, Inc. model and their role is
to ensure that patients fully understand their conditions and
collaboratively develop an action plan to improve their
health status. The CHCs include registered dietitians, certi-
fied diabetes educators, registered nurses, certified tobacco
treatment specialists (trained at the Mayo clinic), and exer-
cise physiologists—all of whom have extensive experience in
patient counseling and motivational interviewing. CHCs are
fully trained to review the comprehensive HDL, Inc. labo-
ratory report with patients, develop therapeutic lifestyle in-
terventions to reduce disease burden, and help patients
achieve optimal health outcomes. CHCs interact with clients
in many different ways, including live or telephonic coun-
seling sessions and group classes. Their services are tailored
to each patient (eg, individualized diet, stress management,
exercise plans for weight control and cardiovascular risk
reduction, practical shopping/cooking education).
The motivation behind the deployment of CHCs stems
from recent studies showing that, despite well-publicized
guidelines on the appropriate management of these diseases
and their prevention, risk-reducing practices often are im-
plemented inconsistently and difficult to sustain, especially in
high-risk, vulnerable populations.10 Yet it has been estimated
that if all patients received the recommended prevention ac-
tivities, myocardial infarctions and strokes could be reduced
by 63% and 31%, respectively, in the next 30 years.11 The
Diabetes Prevention Program (DPP), a large study of people at
high risk for diabetes, also showed that lifestyle intervention
to lose weight and increase physical activity reduced the de-
velopment of type 2 diabetes by 58% during a 3-year period.8
The objective of the present study was to evaluate the
impact of HDL, Inc.’s comprehensive care model on cost and
quality of care. Total cost of care was examined as well as the
distribution of costs among various types of health services
(eg, inpatient services, ambulatory services). Quality of care
was measured by frequency of adverse events and im-
provements in laboratory values associated with lower risk
for future adverse events.
122 THOMPSON ET AL.
Methods
Study design
The study was an observational, retrospective case-control
cohort study (complete details of the study design are
available from the authors upon request) utilizing adminis-
trative pharmacy and medical claims data, and clinical data
for a subset of patients. Total cost of care was based on actual
medical claims data that were gathered independently and
analyzed by HealthCore (Wilmington, DE), a health services
research company. The study consisted of 2 cohorts, the HDL
cohort and the control cohort.
Using the International Classification of Diseases, Ninth Re-
vision (ICD-9) codes shown in Table 1 as inclusion criteria
resulted in at-risk patient cohorts for whom, absent effective
intervention, medical complications were more likely to
occur in the near term. The ICD-9 codes in Table 1 also
represent preexisting conditions for which ongoing medical
management likely would benefit from the information in-
cluded in HDL, Inc. panels. All subjects in this study were
between 18 and 64 years old. To be included in the HDL
cohort, individual subjects must have undergone at least 2
HDL, Inc. panels between June 1, 2010 and May 31, 2011
(inclusive). The control cohort included subjects who had at
least 2 traditional lipid panels between June 1, 2010 and May
31, 2011 (inclusive). Finally, only members of the HDL cohort
and control cohort who had 3 years of continuous health
plan eligibility during their observation window were re-
tained in the analytic file. The date of the first lipid panel was
selected as the index date for each subject. As a result, all
subjects had a full 12 months of baseline data and between 13
and 24 months of follow-up data.
At the first stage of the selection of the control cohort,
Nearest Neighbor Propensity Score Matching, with a 0.02
caliper was used to develop a 1:1 match of controls to the
HDL cohort during the initial identification of the control
cohort members. Matching was based on Deyo-Charlson Co-
morbidity Index, state of residence, age, sex, known coronary
artery disease, history of ischemic stroke, previous percuta-
neous coronary intervention, previous coronary artery by-
pass graft surgery, and the variables listed in Table 1.
Results
The final study sample consisted of 443 participants; 229
were followed in the HDL cohort and 214 were followed in
the matched control cohort. The average age of both cohorts
was 51. The ratio of males was 65% in the HDL cohort and
66% in the matched control cohort. Although there were
participants from all geographic regions, 94% were from the
southeastern region of the United States (detailed descriptive
analyses of the demographic and comorbidity characteristics
of the HDL cohort and the control cohort are available from
the authors upon request).
Figure 1A shows the study results for average total
monthly cost of care during the 2-year follow-up period.
Costs shown are average monthly costs per cohort member
that have been aggregated over the amount of follow-up
time they contributed to the study. During the follow-up
period, when medical management included HDL, Inc. ser-
vices, the average total monthly cost of care was significantly
lower by 23% (-$150.00, P < 0.01) compared to controls after
adjusting for baseline differences in total health care costs.
Interestingly, the reduction in total costs was seen despite
higher costs observed in the HDL cohort during the baseline
year before the first HDL, Inc. test panel. As shown in Figure
1B, total cost of care decreased over time, which suggests the
benefit of including HDL, Inc. services accrued over time.
As shown in Figure 2A the overall decrease in average
monthly cost of care for the HDL cohort was related to a
statistically significant decrease in the cost of treating ad-
verse events requiring inpatient care (-$114.00, P < 0.01). The
reduction in average monthly cost of inpatient care also
corresponded with numerically lower rates of hospitalization
and emergency room costs (Fig. 2B).
Table 1. ICD-9 Code Study Inclusion Criteria
Disorder ICD-9 Code(s)
Coronary atherosclerosis, native artery 414.xx
Intermediate coronary syndrome 411.xx
Pure hypercholesterolemia 272.0x
Pure hyperglyceridemia 272.1x
Mixed hyperlipidemia 272.2x
Unspecified hyperlipidemia 272.4x
Dysmetabolic syndrome X 277.7x
Essential hypertension 401.xx
Obesity, unspecified (BMI 30.0–39.9) 278.00
Morbid obesity (BMI 40 or greater) 278.01
Overweight (BMI 25.0–29.9) 278.02
Hypertensive heart disease 402.xx
Hypertensive chronic kidney disease 403.xx
Diabetes type II not uncontrolled 250.x0
Diabetes type II uncontrolled 250.x2
Disorders of thyroid gland 240.xx–246.xx
BMI, body mass index; ICD-9, International Classification of Diseases,
Ninth Revision.
FIG. 1. Total monthly cost of care
of patients utilizing HDL, Inc. ser-
vices compared to matched con-
trols. HDL, Health Diagnostic
Laboratory; PMPM, per member
per month.
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In addition to the reduction in acute care costs, Figures 2C
and 2D show that although cost of physician office visits was
not significantly higher ($4.00, P = 0.331), the HDL cohort
experienced a lower cost of all other outpatient services
(-$55.00, P = 0.02). Other outpatient services represent all
ambulatory services not provided by physicians as part of a
routine office visit (eg, kidney dialysis, radiological imaging,
ambulatory surgical procedures). These cost reductions cor-
responded with generally lower utilization rates of outpa-
tient services.
Although the relatively small sample size in the present
analysis was sufficient to demonstrate significant cost re-
ductions, this study was not appropriately powered to show
statistically significant reductions in adverse events. How-
ever, numerical trends suggest the HDL cohort experienced
fewer total adverse events during the follow-up period. Im-
portantly, diabetes complications (the most frequently ob-
served adverse events tracked in this study) occurred at less
than half the rate observed in the control cohort (Hazard
Ratio = 0.44, P = 0.11; Fig. 3).
Furthermore, statistically significantly greater improve-
ments in lipid markers were achieved in the HDL cohort
compared to controls (Fig. 4A and 4B). Low-density lipo-
protein cholesterol (LDL-C) and triglyceride levels for the
control group were obtained from the claims data. By the
end of the follow-up period, the average LDL-C level within
the HDL cohort had been reduced to below 100mg/dL, the
level recommended by the American Heart Association for
those with or at risk for heart disease. Approximately 54%
of patients in the HDL cohort achieved serum LDL-C levels
below 100mg/dL compared to 37% in the control group.
Furthermore, 15% of the patients in the HDL cohort
achieved serum LDL-C levels below 70mg/dL compared to
10% in the control group. Based on prior medical research,
the improvement in serum lipid levels in the HDL cohort
suggests those individuals will experience fewer adverse
cardiac events and presumably greater cost reductions in
the future.
In addition, although comprehensive laboratory testing
results were not available for the control group, significant
improvements in several important cardiovascular risk
markers including lipoproteins and apolipoproteins were
observed in the HDL cohort when baseline values were
compared to the last available test (Table 2).13,14
FIG. 2. Average monthly cost of acute and ambulatory care for patients utilizing HDL, Inc. compared to matched controls.
HDL, Health Diagnostic Laboratory; PMPM, per member per month.
FIG. 3. Hazard function for diabetes complications by
Cohort.
124 THOMPSON ET AL.
The significant improvements in lipid levels also were
associated with a statistically significant higher utilization of
statins and niacin by the HDL cohort over the course of the
study. This suggests that physician prescribing practice was
influenced by information contained in the HDL, Inc. panel
results. At the same time, total pharmaceutical costs during
the follow-up period for the HDL cohort and the control
cohort were not statistically significantly different ($135.00
and $114.00 per member per month, respectively, P = 0.182).
Because a complete HDL, Inc. panel includes a number
of relatively expensive tests, including genetic screening,
higher laboratory costs in the HDL cohort were expected.
However, total laboratory costs for the HDL cohort and the
control cohort during the follow-up period when those
panels were performed were not statistically significantly
different ($66.00 and $60.00 per member per month, respec-
tively, P = 0.241).
Discussion
The reductions in both utilization and cost observed in the
present study lend support to HDL, Inc.’s model for patient
care, in which advanced diagnostics, aggressive disease state
management, and personalized health and wellness advice
collectively help to coordinate the delivery of care.
However, further research is needed to understand the
mechanisms resulting in these improvements in risk bio-
markers and health care costs. For example, it is possible that
physicians who are well versed in comprehensive, advanced
testing may use HDL, Inc. services more frequently and may
treat their high-risk patients more aggressively, and thereby
play a moderating role in the outcomes observed. Many of
the utilization and outcome metrics considered in this anal-
ysis did not yield statistically significant differences between
the HDL cohort and the control cohort, possibly because of
the small sample size and relatively short follow-up time;
hence, future research should evaluate costs and outcomes
over a longer time period and across a greater number of
patients.
Nevertheless, it is important to note that the improvements
in risk factors and reductions in cost observed in the HDL
cohort support HDL, Inc.’s model of tightly coupling ad-
vanced laboratory services with prevention and disease
management programs. Clinical laboratories such as HDL, Inc.
are able to offer an increasingly wide array of tools to enhance
the effectiveness of these programs. For example, improved
risk stratification with a comprehensive panel of biomarkers
allows prevention efforts to be appropriately focused most
aggressively on those patients most likely to benefit, and
identify those who would benefit from treatment who would
be missed using traditional approaches.15 The enhanced utili-
zation of statins observed in the present study is consistent
with this intention; the point being that without advanced
testing, many such patients would not have been identified as
high risk and may not have been treated at all. The ability to
predict responses to particular drug treatments more accu-
rately promises to enhance the effectiveness of medical man-
agement while reducing adverse events and consequent
FIG. 4. Significantly greater im-
provements in LDL-C (A) and triglyc-
erides (B) were observed in the HDL
cohort compared to controls during the
study period. HDL, Health Diagnostic
Laboratory; LDL-C, low-density lipo-
protein cholesterol; * denotes P< .05.
Table 2. Improvements in Cardiovascular Risk Markers in the HDL Cohort from the First Test
to the Most Recent Available Test Results, Inter-Test Interval = 63 – 2 Weeks
Baseline Follow-Up
Marker Mean SEM Mean SEM N P Value
APO B 93.9 1.7 85.4 1.7 207.0 < 0.0001
LDL-P 1624.6 36.7 1469.3 38.0 183.0 < 0.0001
Small Dense
LDL-C 32.9 1.0 27.9 0.9 198.0 < 0.0001
HDL-C 50.4 0.9 51.3 1.0 213.0 0.2359
APO A1 147.3 2.1 146.7 2.1 209.0 0.6767
HDL2-C 10.8 0.5 13.7 0.5 202.0 < 0.0001
Homocysteine 11.4 0.3 10.7 0.3 128.0 < 0.01
Vitamin D 29.7 1.1 33.4 1.1 107.0 < 0.01
APO B, apolipoprotein B; APO A1, apolipoprotein A-1; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; LDL-P, low-density lipoprotein particles; SEM, standard error of mean.
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costs.16–18 Tools to access and share historical trends in labo-
ratory markers can quickly support and enhance informa-
tional continuity and coordination of care. Perhaps most
importantly, engaging patients in this process in a way that is
personally meaningful, while educating and empowering
them to track and participate in achieving their health goals,
has great potential to improve patient compliance.19
Conclusion
Although additional research is warranted, as providers
and payers seek to improve outcomes, lower total cost of
care, and improve the wellness of the populations they serve,
this study’s results suggest that clinical laboratory service
providers can evolve to play an important role in the coor-
dination and design of patient care plans that achieve those
goals. PCMH and ACO initiatives should consider including
clinical laboratory service providers with comprehensive
care models, such as HDL, Inc., and should evaluate how
other ancillary care providers can evolve to play important
roles in the design and delivery of health care services.
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